Ocugen, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Histogenics Corporation (to 2022)
11
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 11, 2027The maintenance fee for Ophthalmic Compositions and Methods of Use (US 10,555,947) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,701,940 | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,149,562 | Method for use of a double-structured tissue implant for treatment of tissue defects In force · From the USPTO record | In force | From the USPTO record | |
| US 9,687,590 | Double-structured tissue implant and a method for preparation and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,842,610 | Method for use of a double-structured tissue implant for treatment of tissue defects In force · From the USPTO record | In force | From the USPTO record | |
| US 9,393,347 | Double-structured tissue implant and a method for preparation and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,993,326 | Method for use of a double-structured tissue implant for treatment of tissue defects In force · From the USPTO record | In force | From the USPTO record | |
| US 9,421,304 | Method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant In force · From the USPTO record | In force | From the USPTO record | |
| US 11,648,102 | Method for Use of a Double-Structured Tissue Implant for Treatment of Tissue Defects In force · Low confidence | In force | Low confidence | |
| US 12,344,860 | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,921,109 | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 18: 1 patent in force now held by others · 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 1 abandoned · 2 no status recorded